Patents Assigned to National Jewish Medical and Research Center
-
Publication number: 20080207556Abstract: Disclosed are compositions and methods for the inhibition of biofilm formation or reduction of existing or developing biofilms in a patient. These methods also inhibit the aggregation of bacteria that form biofilms in the airways. The methods include administering to a subject that has or is at risk of developing biofilms a compound or formulation that inhibits the formation or polymerization of actin microfilaments or depolymerizes actin microfilaments at or proximal to the site of biofilm formation. Such a compound can be administered in combination with a compound or formulation that inhibits the accumulation or activity of cells that are likely to undergo necrosis at or proximal to the site of biofilm formation (i.e., neutrophils). The methods and compositions can further include the use of anti-DNA and/or anti-mucin compounds, as well as other therapeutic compounds and compositions.Type: ApplicationFiled: May 6, 2008Publication date: August 28, 2008Applicant: NATIONAL JEWISH MEDICAL AND RESEARCH CENTERInventors: Jerry A. Nick, Travis S. Walker, G. Scott Worthen
-
Publication number: 20080199509Abstract: The invention relates to methods of inhibiting biofilm formation or reducing biofilms in a subject or on a device or surface by administering a charged compound such as a polyamino acid to a subject, device or surface. The invention also relates to compositions for inhibiting biofilm formation or reducing biofilms.Type: ApplicationFiled: February 14, 2008Publication date: August 21, 2008Applicant: NATIONAL JEWISH MEDICAL AND RESEARCH CENTERInventors: Jerry A. Nick, Quinn M. Parks
-
Patent number: 7374934Abstract: The present invention relates to novel immortalized precursor cell populations derived from embryonic stem cell populations and methods to produce such cell populations. Also disclosed is an assay to identify regulatory compounds capable of controlling cell growth for therapeutic and experimental use.Type: GrantFiled: August 13, 2002Date of Patent: May 20, 2008Assignee: National Jewish Medical and Research CenterInventors: Gordon M. Keller, Robert G. Hawley, Kyunghee Choi
-
Publication number: 20080085883Abstract: The present invention relates, in one embodiment, to a method of preventing or treating diabetes using low molecular weight antioxidants. In a further embodiment, the invention relates to a method of protecting and/or enhancing viability of cells/tissues/organs during isolation (harvesting), preservation, expansion and/or transplantation. In yet another embodiment, the present invention relates to a method of inducing immune tolerance. The invention also relates to compounds and compositions suitable for use in such methods.Type: ApplicationFiled: September 19, 2007Publication date: April 10, 2008Applicants: AEOLUS SCIENCES, INC., National Jewish Medical and Research Center, University of Colorado Health Sciences Center, Children's Hospital of PittsburghInventors: Jon PIGANELLI, Kathryn HASKINS, Sonia FLORES, James CRAPO, Brian DAY, Ronald GILL, Richard GAMMANS, Manisha PATEL
-
Publication number: 20080086070Abstract: A joint aspirate-facilitating device is provided including a flexible main panel that is secured to the joint to be aspirated. An inflatable bladder is secured to the main panel and is placed in contact with the soft tissues overlying and surrounding the joint space. The bladder is used to apply pressure to selected areas of the joint to compress the fluid sacs in the joint. An access opening is formed in the main panel designating the location where joint fluid is to be aspirated. The joint fluid is directed to flow to the area of the joint exposed at the access opening based on the shape of the bladder that compresses surrounding areas of the fluid sacs. A conventional hand pump may pressurize the bladder or the bladder may be filled with a viscous gel material to generate pressure. Multiple access openings may be formed on the main panel designating locations where aspiration is to be conducted.Type: ApplicationFiled: October 6, 2006Publication date: April 10, 2008Applicant: NATIONAL JEWISH MEDICAL AND RESEARCH CENTERInventor: Richard Meehan
-
Publication number: 20080070256Abstract: Disclosed are non-human animal models, and preferably, rodent models, and more preferably, mouse models, of B-cell Non-Hodgkin's Lymphoma (NHL). In particular, the present invention provides animal models of B cell NHL including, B cell chronic lymphocytic leukemia/lymphoma (B-CLL), Burkitt's lymphoma (BL), Follicular-like lymphoma (FLL) and Diffuse large B-cell lymphoma (DLBCL), as well as various methods for producing these non-human animal models. These animal models, as well as cell lines produced from or derived from these models, are useful tools for a variety of methods, including, but not limited to, preclinical testing of drug candidates, and particularly drug candidates that are specific for human proteins, and any research, development, pharmaceutical, or clinical purpose, including but not limited to, the identification, development, and/or testing of drugs (therapeutics, prophylactics, etc.Type: ApplicationFiled: July 26, 2007Publication date: March 20, 2008Applicant: NATIONAL JEWISH MEDICAL AND RESEARCH CENTERInventors: Yosef Refaeli, Brian Turner, Ryan Young
-
Publication number: 20080064103Abstract: Particular members of the multisubunit immune recognition receptor (MIRR) family of receptors, specifically, the B cell antigen receptor (BCR), the pre-B cell receptor (pre-BCR), the pro-B cell receptor (pro-BCR), Ig Fc receptors (FcR), and NK receptors, can be physically uncoupled from their associated transducers. The invention describes regulatory compounds and methods for mimicking such dissociation/destabilization for the purposes of receptor desensitization and for treatment of conditions in which receptor desensitization or alternatively, enhanced or prolonged receptor sensitization, is desirable. Compounds and methods for enhancing or prolonging receptor sensitization are also disclosed, as are methods for identifying regulatory compounds suitable for use in the present methods.Type: ApplicationFiled: July 2, 2007Publication date: March 13, 2008Applicant: NATIONAL JEWISH MEDICAL AND RESEARCH CENTERInventors: Barbara Vilen, John Cambier
-
Publication number: 20080063629Abstract: An in vitro method for the differentiation of functionally mature neutrophils from stem cells is disclosed. Also disclosed are methods of producing genetically modified neutrophils in vitro and methods of using the neutrophils produced according to the invention.Type: ApplicationFiled: June 5, 2007Publication date: March 13, 2008Applicant: NATIONAL JEWISH MEDICAL AND RESEARCH CENTERInventors: Jonathan Lieber, George Worthen, Saiphone Webb, Gordon Keller
-
Publication number: 20080031865Abstract: Disclosed are compositions and methods for decreasing the viscosity and/or cohesiveness of and/or increasing the liquefaction of excessively or abnormally viscous or cohesive mucus or sputum. The composition contains a protein or peptide containing a thioredoxin active-site in reduced state and optionally further contains a reducing system.Type: ApplicationFiled: March 2, 2007Publication date: February 7, 2008Applicant: NATIONAL JEWISH MEDICAL AND RESEARCH CENTERInventor: Carl White
-
Publication number: 20070269426Abstract: Disclosed is a method of using soluble ?? T cell receptors to regulate a ?? T cell-mediated immune response in a mammal.Type: ApplicationFiled: April 3, 2007Publication date: November 22, 2007Applicant: NATIONAL JEWISH MEDICAL AND RESEARCH CENTERInventors: Rebecca O'Brien, Willi Born, Christina Roark, M. Aydintug
-
Publication number: 20070243214Abstract: Disclosed is a panel of biomarkers associated with angiogenesis, and the use of such biomarkers (genes, proteins, homologues and analogs thereof) to regulate angiogenesis. Methods for identifying compounds useful for regulating angiogenesis and conditions related thereto are disclosed.Type: ApplicationFiled: October 2, 2006Publication date: October 18, 2007Applicant: National Jewish Medical and Research CenterInventors: William Schiemann, Allan Albig
-
Patent number: 7282477Abstract: Disclosed are Cystatin C (CysC) homologues, including CystC homologues that act as antagonists or inhibitors of transforming growth factor-? (TGF-?). Also disclosed are methods to identify CystC homologues that are antagonists or inhibitors of TGF-? and compositions and therapeutic methods using CystC and homologues thereof to regulate the activity of TGF-?, and TGF-?-mediated tumor malignancy and invasion and other TGF-?-mediated fibrotic or proliferative conditions and diseases.Type: GrantFiled: October 15, 2004Date of Patent: October 16, 2007Assignee: National Jewish Medical and Research CenterInventor: William P. Schiemann
-
Publication number: 20070179087Abstract: This invention relates to a method to protect a mammal from a disease associated with an inflammatory response, and in particular, from an inflammatory disease characterized by eosinophilia, airway hyperresponsiveness and/or a Th2-type immune response. The method includes administration of a heat shock protein to a mammal having such a disease. Formulations useful in the present method are also disclosed.Type: ApplicationFiled: September 25, 2006Publication date: August 2, 2007Applicant: National Jewish Medical and Research CenterInventors: Erwin Gelfand, Katalin Lukacs, Angela Haczku
-
Publication number: 20070149498Abstract: The present invention relates, in general, to cancer therapy, and, in particular, to a method of preventing or treating cancer using low molecular weight antioxidants (e.g., mimetics of superoxide dismutase (SOD)) as the active agent or as a chemo- and/or radio-protectant. The invention also relates to compounds and compositions suitable for use in such a method.Type: ApplicationFiled: November 9, 2006Publication date: June 28, 2007Applicants: Aeolus Sciences, Inc., National Jewish Medical and Research Center, Duke UniversityInventors: James Crapo, Brian Day, Ines Batinic-Haberle, Richard Gammans, Zeljko Vusjaskovic
-
Publication number: 20070116691Abstract: Disclosed are methods for conditionally immortalizing stem cells, including adult and embryonic stem cells, the cells produced by such methods, therapeutic and laboratory or research methods of using such cells, and methods to identify compounds related to cell differentiation and development or to treat diseases, using such cells. A mouse model of acute myeloid leukemia (AML) and cells and methods related to such mouse model are also described.Type: ApplicationFiled: October 18, 2006Publication date: May 24, 2007Applicants: NATIONAL JEWISH MEDICAL AND RESEARCH CENTER, THE REGENTS OF THE UNIVERSITY OF COLORADOInventors: John Cambier, Yosef Refaeli, Sara Johnson, Brian Turner
-
Patent number: 7195766Abstract: Disclosed are compositions and methods for decreasing the viscosity and/or cohesiveness of and/or increasing the liquefaction of excessively or abnormally viscous or cohesive mucus or sputum. The composition contains a protein or peptide containing a thioredoxin active-site in reduced state and optionally further contains a reducing system.Type: GrantFiled: September 10, 2003Date of Patent: March 27, 2007Assignee: National Jewish Medical and Research CenterInventor: Carl W. White
-
Patent number: 7189707Abstract: The present invention relates, in general, to a method of modulating physiological and pathological processes and, in particular, to a method of modulating cellular levels of oxidants and thereby processes in which such oxidants are a participant. The invention also relates to compounds and compositions suitable for use in such methods.Type: GrantFiled: January 23, 2003Date of Patent: March 13, 2007Assignees: National Jewish Medical Research Center, Duke University, Aeolus Sciences, Inc.Inventors: James D. Crapo, Brian J. Day, Michael P. Trova, Polivina Jolicia F. Gauuan, Douglas B. Kitchen, Irwin Fridovich, Ines Batinic-Haberle
-
Publication number: 20070048802Abstract: Disclosed is a rapid, non-invasive and highly specific and sensitive diagnostic assay for the identification of individuals with autoimmune chronic urticaria, which makes use of CD203c, and in some embodiments, additional proteins, as a marker for the disease. Test kits for diagnosis of an individual suspected of having autoimmune chronic urticaria are also disclosed. Also disclosed are a method of identifying compounds useful for treating autoimmune chronic urticaria and a method of treating autoimmune chronic urticaria.Type: ApplicationFiled: March 21, 2006Publication date: March 1, 2007Applicant: National Jewish Medical and Research CenterInventors: Ronald Harbeck, Karen Andrews, Donald MacGlashan
-
Patent number: 7169570Abstract: Disclosed are methods for evaluating the activation of Bcl10 in a cell in response to a putative stimulus, as well as methods for evaluating or identifying a regulatory compound which regulates activation of Bcl10-mediated signal transduction. These methods utilize the discovery of the activation-dependent formation in a cell of Bcl10 aggregates in a cell.Type: GrantFiled: March 4, 2004Date of Patent: January 30, 2007Assignee: National Jewish Medical and Research CenterInventors: Brian C. Schaefer, Philippa Marrack, John W. Kappler
-
Patent number: 7160681Abstract: Disclosed are methods for assessing tumor cell growth in a patient for the diagnosis, monitoring and/or staging of tumor development. The method include the identification of reduced cdk6 expression or biological activity as an indicator of increased cell growth in a cell sample. The methods further include the identification of compounds which regulate cdk6 and the use of such compounds in a method for the regulation of inappropriate cell growth.Type: GrantFiled: May 22, 2002Date of Patent: January 9, 2007Assignee: National Jewish Medical and Research CenterInventors: Erwin W. Gelfand, Joseph J. Lucas